LUCDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Lucid Diagnostics Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$0.38−0.10 (-21.05%)

Close on Oct 19, 2026

Market cap: $69.11M
P/E (TTM): –
Dividend yield: –

Lucid Diagnostics Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Depreciation & Amortization	0.87	1.17	2.50	1.94	0.00	–
Stock-Based Compensation	4.49	4.53	5.76	14	9.13	0.07
Change in Accounts Receivable	-0.60	0	-0.03	0.18	-0.20	–
Change in Accounts Payable	-0.27	0.10	0.09	-0.45	-0.67	1.15
Operating Cash Flow	-46	-44	-33	-30	-18	-5.63
Capital Expenditures	-0.20	-0.30	–	-3.20	-0.86	–
Investing Cash Flow	-0.20	-0.65	-0.22	-4.11	-0.86	–
Stock Issued	–	–	–	1.81	–	–
Debt Issued	–	–	–	–	–	7.94
Debt Repaid	–	-2.65	–	–	–	–
Financing Cash Flow	59	48	29	2.61	72	5.58
Net Change in Cash	12	3.46	-3.58	-31	54	-0.05
Free Cash Flow	-47	-44	–	-33	-19	–
Income Taxes Paid	–	0	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: -36.1%
Operating margin: -930.9%
Net margin: -959.8%
Return on equity, FY2025: -710.6%

Financial strength

Current ratio: 1.33
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 121.4%

Valuation

P/E ratio: –
Price to sales: 12.69
Price to book: 6.32
Dividend yield: –